Detalles de la búsqueda
1.
Dapagliflozin pharmacokinetics is similar between patients with heart failure with reduced ejection fraction and patients with type 2 diabetes mellitus.
Br J Clin Pharmacol
; 90(2): 606-612, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37897064
2.
Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies.
Br J Clin Pharmacol
; 89(9): 2691-2702, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37055941
3.
Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus.
Br J Clin Pharmacol
; 88(4): 1942-1946, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34687551
4.
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF.
Circulation
; 142(11): 1040-1054, 2020 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32673497
5.
A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes.
Diabetes Obes Metab
; 23(4): 991-1000, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33368935
6.
Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials.
Diabetes Obes Metab
; 23(5): 1101-1110, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33394543
7.
Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial.
J Pharmacol Exp Ther
; 375(1): 76-91, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32764153
8.
Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.
Diabetes Obes Metab
; 22(12): 2493-2498, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32803900
9.
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
Diabetes Obes Metab
; 22(5): 798-806, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31912603
10.
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
JAMA
; 323(14): 1353-1368, 2020 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32219386
11.
Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Cardiovasc Diabetol
; 18(1): 138, 2019 10 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31640705
12.
Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus.
Diabetes Obes Metab
; 21(6): 1381-1387, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30756462
13.
Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
Diabetes Obes Metab
; 21(4): 876-882, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30499157
14.
Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus.
Diabetes Obes Metab
; 21(4): 829-836, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30456904
15.
Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
Diabetes Obes Metab
; 21(12): 2667-2673, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31407856
16.
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors.
Diabetes Obes Metab
; 21(12): 2684-2693, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31423699
17.
Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus.
Br J Clin Pharmacol
; 85(8): 1820-1828, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31077437
18.
Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Am J Physiol Renal Physiol
; 315(5): F1295-F1306, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30019930
19.
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis.
Diabetes Obes Metab
; 20(3): 479-487, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29024278
20.
Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: A quantitative assessment using an integrative systems pharmacology model.
Diabetes Obes Metab
; 20(8): 2034-2038, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29663628